Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced a first-patient-dosed for a Phase 1/2 clinical trial. This… Read More »Opus Genetics Inc., has announced a first-patient-dosed in a Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.
Researchers at the Institute for Vision Research, University of Iowa, USA, and Ophthalmology and Visual Sciences, Duke-NUS Graduate Medical School, Singapore, have reported a publication… Read More »Research on clinical trial outcomes for XLRS have proposed prolonged trial periods in order to assess disease stabilization.
Researchers at the Laboratory for Retinal Gene Therapy, Department of Ophthalmology, University Hospital Zurich, Switzerland, have reported a novel treatment approach aimed to expand the… Read More »Researchers at University Hospital Zurich have reported a novel dual AAV strategy aimed to correct ABCA4 gene mutations for Stargardt disease (STGD1).
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the November 15th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »November 15th, 2023 “EURETINA-Brief”© Issue No. 281
Samsung Bioepis announced that the FDA (Food and Drug Administration) has approved the supplemental biologics license application (BLA) for Byooviz (ranibizumab-nuna) as a biosimilar product… Read More »Samsung Bioepis’ supplemental of Byooviv has being approved by FDA for an interchangeable intravitreal injection in neovascular AMD, RVO and myopic CNV
At the recent 23rd EURETINA Congress on October 8th in Amsterdam, the Netherlands, Professor Richard Gale, based at the Hull York Medical School, University of… Read More »EURETINA Congress presentation on patient mental health and caregiver burden in AMD.
Researchers have published a study showing that genetic missense alterations on KCNV2-asscociated retinopathy may appear to hold better visual acuity and greater structural integrity (Guimaraes… Read More »Researchers at Moorfields Eye Hospital have reported valuable genotype-phenotype correlations on KCNV2-associated retinopathy
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the October 22nd, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »October 22nd, 2023 “EURETINA-Brief”© Issue No. 280
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced its “first-in-patient” in a Phase 1/2 clinical trial for… Read More »Opus Genetics Inc., has announced the “first-in-patient” in a Phase 1/2 clinical trial for “OPGx-001” for the treatment of LCA5 retinal disease.
Clinical researchers from the US, Canada and the Netherlands, have reported a study to recommend clinical trial designs and outcomes for XLRP (X-linked retinitis pigmentosa). … Read More »Clinical trial development and trial outcome measures have published recommendations for XLRP studies.
